Ruthenium(II) Arene Compounds as Versatile Anticancer Agents
DOI:
https://doi.org/10.2533/chimia.2009.217Keywords:
Anticancer, Bioorganometallic, Chemotherapy, RutheniumAbstract
Ruthenium-based compounds are an attractive alternative to clinically used platinum drugs due to several features including a wide range of accessible oxidation states, varied synthetic chemistry and typically lower general toxicities. One series of ruthenium(II)-arene-pta, RAPTA (pta = 1,3,5-triaza-7-phosphatricyclo[3.3.1.1] decane) compounds has been found to show particularly high selectivity towards cancer cells in both in vitro and in vivo studies.Downloads
Published
2009-04-29
Issue
Section
Scientific Articles
License
Copyright (c) 2009 Swiss Chemical Society
![Creative Commons License](http://i.creativecommons.org/l/by-nc/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
[1]
A. Renfrew, Chimia 2009, 63, 217, DOI: 10.2533/chimia.2009.217.